Welcome to our dedicated page for Alpha Cognition SEC filings (Ticker: ACOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alpha Cognition Inc. filings document the regulatory record of a British Columbia biopharmaceutical issuer with no-par-value common shares listed on Nasdaq under ACOG. The disclosures identify the company as an emerging growth company and cover formal reporting around ZUNVEYL commercialization, financial results, operational updates, and capital and compensation arrangements.
Recent Form 8-K filings address results of operations, Regulation FD disclosures, board appointments and departures, equity awards under incentive plans, and material agreements tied to legacy Memogain asset and license obligations. Proxy materials describe annual general meeting matters, including director elections, board size, auditor appointment, shareholder voting procedures, and accompanying annual financial statement materials.
Opaleye Management Inc., a 10% owner of Alpha Cognition Inc. (ACOG), reported a series of open-market share purchases in late March 2026. An affiliated fund, Opaleye, L.P., bought 4,182 common shares at $5.59 on March 24, 8,581 shares at a weighted average $5.4281 on March 25, and 7,319 shares at a weighted average $5.2842 on March 26.
Following these transactions, the fund held 2,460,000 Alpha Cognition common shares indirectly through Opaleye, L.P., and a separately managed account held an additional 90,000 shares. The filing notes these holdings are reported indirectly through Opaleye Management Inc., which disclaims beneficial ownership beyond its pecuniary interest.
Alpha Cognition Inc. reported its fourth quarter and full-year 2025 results, highlighting early commercial traction for Alzheimer’s drug ZUNVEYL. Full-year 2025 revenue was $10.2 million, including $6.8 million in net product sales and $3.4 million in licensing revenue. Fourth-quarter 2025 ZUNVEYL net product revenue reached $2.5 million.
Bottles dispensed in the fourth quarter rose 62% sequentially to 4,941, with December the strongest month since launch. Year-end 2025 cash and cash equivalents were $66.0 million, up from $48.5 million a year earlier, supporting the company’s goal of reaching operational profitability in 2027. The company reported a 2025 net loss of $20.7 million, compared with $14.8 million in 2024, as selling, general and administrative expenses increased to $29.1 million to support commercialization.
Alpha Cognition Inc. reported insider activity by Opaleye-managed entities. Opaleye, L.P. purchased 2,481 common shares on March 18, 2026 at a weighted average price of $5.749 and 2,094 shares on March 19, 2026 at a weighted average price of $5.707 in open-market transactions.
After these buys, Opaleye, L.P. reported holding 2,439,918 Alpha Cognition shares, and a separately managed account overseen by Opaleye reported 90,000 shares. Opaleye Management Inc. may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Alpha Cognition Inc. major holder Opaleye Management Inc., through Opaleye, L.P., made an open-market purchase of 1,331 shares of common stock at a weighted average price of $5.782 per share, with individual trade prices ranging from $5.76 to $5.79. Following this purchase, Opaleye, L.P. indirectly holds 2,435,343 shares, and a separately managed account overseen by Opaleye holds 90,000 shares.
Opaleye Management Inc., a more than ten percent owner of Alpha Cognition Inc., reported additional open-market purchases of the company’s common stock. Through Opaleye, L.P., it bought 5,708 shares on March 12, 2026 at a weighted average price of $5.8543 per share and 7,358 shares on March 13, 2026 at a weighted average price of $5.7470, for a total of 13,066 shares. After these transactions, Opaleye, L.P. held 2,434,012 shares, and a separately managed account overseen by Opaleye held 90,000 shares, all reported as indirect ownership. The prices reflect multiple trades within narrow ranges, with Opaleye undertaking to provide detailed breakdowns upon request. Opaleye Management disclaims beneficial ownership except to the extent of its pecuniary interest.
Alpha Cognition Inc. large shareholder Opaleye Management Inc., through its fund Opaleye, L.P., reported open-market purchases of 4,079 shares of Common Stock. The buys occurred on March 6 and March 9, 2026 at weighted average prices of $5.7989 and $5.8477 per share, across trade ranges disclosed in footnotes.
Following these transactions, Opaleye, L.P. held 2,420,946 shares indirectly, and a separately managed account overseen by Opaleye held 90,000 shares. Opaleye Management Inc. states it may be deemed a beneficial owner but disclaims beneficial ownership beyond its pecuniary interest.
Alpha Cognition Inc. insider activity centers on indirect open‑market buying linked to Opaleye entities. Opaleye Management Inc., as investment manager of Opaleye, L.P. and portfolio manager of a separately managed account, may be deemed to beneficially own their holdings but disclaims beneficial ownership beyond its pecuniary interest.
On March 4–5, 2026, Opaleye, L.P. and the managed account purchased a combined 66,818 shares of Alpha Cognition common stock in open‑market transactions. After these trades, Opaleye, L.P. held 2,416,867 shares, and the managed account held 90,000 shares, all reported as indirect ownership.
Alpha Cognition Inc. large shareholder Opaleye Management Inc., through affiliated accounts, reported open-market purchases of a total of 71,411 shares of common stock. The buys occurred on March 2 and March 3, 2026 at weighted average prices of about $5.80 and $5.7502 per share, increasing indirect holdings in the issuer.
Alpha Cognition Inc. amended a Schedule 13G filing to report that Opaleye Management Inc., together with Opaleye, L.P. and James Silverman, beneficially own 2,388,638 common shares, representing 11.00% of the class. The filing states Opaleye, L.P. holds 2,308,638 shares (10.62%), and cites 21,742,104 shares outstanding as reported November 13, 2025.
The Adviser (Opaleye Management Inc.) advises the Fund and Mr. Silverman controls the Adviser; shared voting and dispositive power are reported for the aggregate holdings. Signatures are dated 03/04/2026.
Opaleye Management Inc., as investment manager and portfolio manager for related entities, reported indirect open-market purchases of Alpha Cognition common stock totaling 4,228 shares around $6 per share. Fund-related holdings rose to 2,288,638 shares, and a separately managed account is shown holding 80,000 shares.